 Home > Chemicals Industry > China Chemical > In 2022, China's pharmaceutical manufacturing market will exceed 4 trillion yuan

In 2022, China's pharmaceutical manufacturing market will exceed 4 trillion yuan

 Last Update: 2022-03-08
 Source: Internet
 Author: User

Tags

red chemical

industry products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Chemical Machinery Equipment Network Market Analysis ] With the continuous development of China's economy, people pay more and more attention to their own health, and the demand for related medical products has gradually expanded.
Statistics show that in 2014, the scale of my country's pharmaceutical market has reached 1.
1 trillion yuan, and in the next four years, it has grown to 1.
5 trillion yuan in 2018 with an annual growth rate of 8.
1%.
The industry believes that my country's pharmaceutical market will continue to maintain this growth rate in the future, and the market scale will continue to expand.

Chemical machinery and equipment network market analysis chemical machinery and equipment

It is worth noting that under this background, with the support of national industrial policies and the pull of market demand, my country's pharmaceutical manufacturing industry will also begin to develop rapidly.
It is understood that the pharmaceutical manufacturing industry refers to industries that turn raw materials into new pharmaceutical products after physical or chemical changes, including the chemical pharmaceutical industry (including chemical raw materials and chemical preparation drugs), the traditional Chinese medicine industry (including the manufacturing of Chinese patent medicines and traditional Chinese medicine).
Processing of decoction pieces), biopharmaceutical industry and medical equipment and equipment manufacturing and other sub-sectors.

In recent years, as a sunrise industry encouraged and supported by the state, the pharmaceutical manufacturing industry has been supported by a series of national policies.
For example, on February 9, 2017, the "Several Opinions on Further Reforming and Improving Policies for the Production, Distribution and Use of Pharmaceuticals" was officially released, and the pharmaceutical manufacturing industry was reformed and improved from the three links of production, circulation, and use.
On February 21, 2017, the country issued the "Thirteenth Five-Year" National Drug Safety Plan, which adheres to strict standards, strict supervision, severe punishment, and serious accountability, adheres to source governance, and both symptoms and root causes to promote health China is building to accelerate the innovation and development of the pharmaceutical industry.

　　From September 1, 2019, the new version of "Drug Production License", "Medical Institution Preparation License", and "Drug Business License" and other licenses have been put into use, which has further promoted the standardized development of drug production and business.

　　On the whole, the implementation of these policies has provided a good system and policy guarantee for the healthy development of the pharmaceutical manufacturing industry, while in fact, it has also continued to drive the continuous growth of the pharmaceutical manufacturing market.

　　According to data, from January to December 2016, the total sales revenue of my country's pharmaceutical manufacturing industry (the sum of the sales revenue of industrial enterprises above designated size) reached 2,806.
29 billion yuan, a year-on-year increase of 9.
89%; the total profit reached 300.
290 billion yuan, a year-on-year increase of 14.
30%.
From January to September 2017, the total sales revenue of my country's pharmaceutical manufacturing industry reached RMB 2,171,530 million, an increase of 8.
80% year-on-year; the total profit reached RMB 241.
990 billion, an increase of 16.
80% year-on-year.
In the first half of 2019, my country's pharmaceutical manufacturing enterprises above designated size achieved operating income of approximately 1,222.
75 billion yuan, a year-on-year increase of 8.
5%, and realized total profits of approximately 160.
82 billion yuan, a year-on-year increase of 9.
4%.

　　Following this development trend, the industry predicts that by 2022, my country’s pharmaceutical manufacturing industry will grow at an average annual compound growth rate of approximately 8.
52%, and total sales revenue will reach 4,603.
4 billion yuan; total profits will have an average annual compound growth rate of approximately 12.
50%, reaching 603.
2 billion yuan.
yuan.

　　Overall, the pharmaceutical manufacturing industry has huge room for development and good development prospects, and the overall supply and demand situation will maintain a good development trend.
However, it is worth noting that because drugs are related to the national economy and people’s livelihood, as the population ages, the proportion of chronic diseases such as cardiovascular and cerebrovascular diseases and diabetes will increase, and the consumption level will continue to upgrade.
The adjustment of the demand structure of drugs will accelerate, and the pharmaceutical manufacturing industry It will also develop in a more standardized and scientific direction.

　　Original title: By 2022, China's pharmaceutical manufacturing market will exceed 4 trillion

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.